Shanghai Serum Bio-Technology (SH:688163) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-09-05 04:56Core Viewpoint - Shanghai Sairun Biotechnology Co., Ltd. has completed the registration of business changes and obtained a new business license, reflecting significant corporate governance updates and operational scope adjustments [1][2]. Group 1: Corporate Changes - The company held board and supervisory meetings on July 24, 2025, to approve the cancellation of the supervisory board and changes to the business scope and articles of association [1]. - The company convened a temporary shareholders' meeting on August 11, 2025, to ratify the aforementioned changes [1]. - The updated business registration information includes a registered capital of RMB 108.22 million and a new operational scope that encompasses drug production, import/export, and various medical device services [2]. Group 2: Investor Communication - The company plans to participate in a collective performance briefing for the biotech and CXO industry from September 15, 2025, to discuss its semi-annual results and address investor inquiries [4][5]. - Investors can submit questions from September 8 to September 12, 2025, for discussion during the briefing [7]. - The briefing will be held online at the Shanghai Stock Exchange Roadshow Center, allowing for interactive communication with investors [6][8].